LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

AZN

187.14

-0.06%↓

LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

AZN

187.14

-0.06%↓

LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

AZN

187.14

-0.06%↓

LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

AZN

187.14

-0.06%↓

LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

AZN

187.14

-0.06%↓

Home・Elenco Azioni・MacroGenics Inc

MacroGenics Inc

Chiusa

SettoreSettore sanitario

4.45 -1.55

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

4.31

Massimo

4.53

Metriche Chiave
By Trading Economics
Entrata	-23M -37M
Vendite	-20M 21M
EPS	-0.58
Margine di Profitto	-177.011
Dipendenti	293
EBITDA	-17M -32M

Raccomandazioni
By TipRanks
Raccomandazioni	Acquista
Previsioni per 12 mesi	+39.74% upside

Dividendi
By Dow Jones
Utili prossimi	12 ago 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	100M 288M
Apertura precedente	6
Chiusura precedente	4.45

Notizie sul Sentiment di mercato

By Acuity

92%

5 / 344 Classifica in Healthcare

MacroGenics Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

26 mag 2026, 16:52 UTC

Principali Notizie su Eventi

NYMEX Overview: Brent Crude Futures Up; Iran Warns of Retaliation After US Strike -- OPIS

26 mag 2026, 23:57 UTC

Utili

Sociedad Quimica 1Q Rev $1.76B >SQM

26 mag 2026, 23:57 UTC

Utili

Sociedad Quimica 1Q EPS $1.28 >SQM

26 mag 2026, 23:48 UTC

Discorsi di Mercato

Nikkei May Rise on Continued AI Enthusiasm -- Market Talk

26 mag 2026, 21:54 UTC

Utili

Webco Industries 3Q EPS $11.61 >WEBC

26 mag 2026, 21:54 UTC

Utili

Webco Industries 3Q Sales $179.6M >WEBC

26 mag 2026, 21:48 UTC

Discorsi di Mercato

GE Aerospace's Repair Boom Should Last for Years -- Market Talk

26 mag 2026, 21:00 UTC

Discorsi di Mercato

ESG Roundup: Market Talk

26 mag 2026, 20:58 UTC

Acquisizioni, Fusioni, Takeovers

Uber's $11.6 Billion Bid for DoorDash Rival Is About Future Proofing It From Robots -- Barrons.com

26 mag 2026, 20:50 UTC

Discorsi di Mercato

Tech, Media & Telecom Roundup: Market Talk

26 mag 2026, 20:50 UTC

Discorsi di Mercato

Auto & Transport Roundup: Market Talk

26 mag 2026, 20:50 UTC

Discorsi di Mercato

Financial Services Roundup: Market Talk

26 mag 2026, 19:22 UTC

Discorsi di Mercato

Cryptocurrencies Add to Losses in Afternoon Trading -- Market Talk

26 mag 2026, 19:17 UTC

Discorsi di Mercato

Oil Recovers Some Losses on U.S.-Iran Skirmishes -- Market Talk

26 mag 2026, 18:56 UTC

Discorsi di Mercato

U.S. Natural Gas Futures Slip in Rangebound Trading -- Market Talk

26 mag 2026, 18:03 UTC

Discorsi di Mercato

AutoCanada Faces Soft Demand, Slow Normalization -- Market Talk

26 mag 2026, 17:42 UTC

Discorsi di Mercato

Grains Await Fresh Trading Catalyst -- Market Talk

26 mag 2026, 17:33 UTC

Discorsi di Mercato

Salesforce, Snowflake Could Dispel Software Bear Thesis -- Market Talk

26 mag 2026, 17:21 UTC

Discorsi di Mercato

Canada Faces a Labor Market Squeeze -- Market Talk

26 mag 2026, 16:52 UTC

Discorsi di Mercato

Bonds to Fund Infrastructure for Data Centers Could Be Risky -- Market Talk

26 mag 2026, 16:43 UTC

Discorsi di Mercato

Spotify's Latest Audio Play: Magazine Articles -- Market Talk

26 mag 2026, 16:24 UTC

Discorsi di Mercato

Dollarama's LATAM Slowdown, Australia Costs Seen as Transient -- Market Talk

26 mag 2026, 16:21 UTC

Discorsi di Mercato

Oil Extends Gains As Strikes Add Tension to U.S.-Iran Talks -- Market Talk

26 mag 2026, 16:20 UTC

Discorsi di Mercato

Tech, Media & Telecom Roundup: Market Talk

26 mag 2026, 16:20 UTC

Discorsi di Mercato

Energy & Utilities Roundup: Market Talk

26 mag 2026, 16:20 UTC

Discorsi di Mercato

Financial Services Roundup: Market Talk

26 mag 2026, 16:20 UTC

Discorsi di Mercato

Acquisizioni, Fusioni, Takeovers

Auto & Transport Roundup: Market Talk

26 mag 2026, 16:16 UTC

Discorsi di Mercato

Alberta Separation Threat Poses Headwind for Canada Dollar -- Market Talk

26 mag 2026, 16:01 UTC

Discorsi di Mercato

Bitcoin Lower as Stress Builds for Holders -- Market Talk

26 mag 2026, 15:21 UTC

Discorsi di Mercato

Hyperliquid Pushes Up to New All-Time High -- Market Talk

Confronto tra pari

Modifica del prezzo

MacroGenics Inc Previsione

Obiettivo di Prezzo

By TipRanks

39.74% in crescita

Previsioni per 12 mesi

Media 6.33 USD 39.74%

Alto 9 USD

Basso 4 USD

Basato su 5 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per MacroGenics Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

5 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 5 che hanno fornito valutazioni azionarie a MacroGenics Inc - Dist negli ultimi 3 mesi.

Sentiment

By Acuity

5 / 344 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo MacroGenics Inc

MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.